bacitracin and Azulfidine en tabs Interactions

Interactions between bacitracin and Azulfidine en tabs (sulfasalazine)

sulfasalazine and bacitracin (Moderate Drug-Drug)

MONITOR: Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of nephrotoxicity due to additive effects on the kidney. The use of 5-aminosalicylate or its prodrugs has been associated with rare reports of renal impairment including minimal change nephropathy and acute or chronic interstitial nephritis. Animal studies have also shown the kidney to be the major target organ of 5-aminosalicylate toxicity. Renal lesions including granular and hyaline casts, tubular degeneration, tubular dilation, renal infarct, papillary edema, papillary necrosis, tubular necrosis, interstitial fibrosis, and interstitial nephritis have been observed with large doses.

MANAGEMENT: Caution is advised if 5-aminosalicylate preparations must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, foscarnet, cisplatin, gallium nitrate, lithium, certain immunosuppressants, intravenous bisphosphonates, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function should be evaluated prior to and during 5-aminosalicylate therapy.